Among the 44 candidate proteins (Table S2, Supporting Information), RanBP3, which has been reported to enhance the nuclear export of active β‐catenin, drew our attention.[12] To investigate the biological function of RanBP3 in CRC, CRISPR/Cas9 technology was used to generate RanBP3‐deficient CRC cells (Figure 3C). Here, RANBP3 is linked to colorectal carcinoma.